Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608295 | 0.84 | CNR2 (0.34) | CNR2KDM4EALDH1A1GAAGLA | |
| SCHEMBL13612712 | 0.79 | ALDH1A1 (0.38) | CNR2KDM4EALDH1A1GAAGLA | |
| SCHEMBL16875997 | 0.78 | CNR2 (0.38) | CNR2KDM4EALDH1A1GAAGLA | |
| SCHEMBL2832289 | 0.77 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL16727329 | 0.75 | CNR2 (0.34) | CNR2KDM4EALDH1A1GAAGLA | |
| SCHEMBL16885247 | 0.75 | CNR2 (0.39) | CNR2KDM4EALDH1A1GAAGLA | |
| SCHEMBL425266 | 0.71 | CNR2 (0.37) | CNR2KDM4EALDH1A1GAAGLA | |
| SCHEMBL13472118 | 0.68 | CNR2 (0.33) | CNR2KDM4EALDH1A1GAAGLA | |
| SCHEMBL4114263 | 0.66 | DPP4 (0.36) | CNR2DPP4DPP8DPP9 | |
| SCHEMBL15133037 | 0.64 | CNR2 (0.34) | CNR2ALDH1A1SMN1; SMN2TSHRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| EP-1888546-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125805-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | PDGFRA, PDGFRB, PF4 | CNR2 1653/4885KDM4E 2036/4885ALDH1A1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.